All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Highlights from ASH 2016: Abstract 100 – A Phase II Study of Pracinostat and Azacitidine in Elderly Patients with AML Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit
On Saturday 3rd December, at the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH) in San Diego, CA, there was a gripping session focusing on “Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation.”
Guillermo Garcia-Manero, MD, of the Department of Leukemia at The University of Texas M.D. Anderson Cancer Center, Houston, USA, presented the key findings from a phase II study of pracinostat and azacitidine. Pracinostat is a potent oral Class I, II, IV Histone Deacetylase (HDAC) inhibitor and azacitidine (AZA) is a novel hypomethylating agent. Garcia-Manero et al. investigated the combination of these agents in 50 older patients (median age 75 years) unable to undergo induction chemotherapy.
The findings were:
- Complete Response (CR) was achieved in 21 patients
- CR with incomplete blood count recovery (CRi) in 2 patients
- Morphologic Leukemia Free status (MLFs) in 3 patients
- cCR rate of 52%
- Median duration of cCR was 13.2 months
- Median Overall Survival (OS) was 19.1 months, 1-year and 2-year OS were 62% and 41%, respectively
- OS by cytogenetic risk group, high vs intermediate; 13.5 months vs 24.1 months
- OS in de novo vs secondary AML, 13.0 months vs 19.6 months
- OS in ≥ 75 years vs < 75 years; 13.5 months vs 22.8 months
- OS by ECOG Performance Status (PS), PS 0–1 vs PS 2; 19.1 months vs 13.0 months
- Thrombocytopenia was the most common grade ≥ 3 hematologic adverse event (46%)
The authors concluded that pracinostat + AZA led to a high rate of response in elderly patients with AML. Furthermore, the responses were durable and observed irrespective of age, cytogenetic risk, ECOG performance status, and de novo or secondary AML.
References